In patients with relapsed and refractory myeloma, when BTZ was given twice weekly via IV route at the standard dose of 1.3 mg/m2, 23% patients developed mild treatment related neuropathy, while 14% developed severe neuropathy. Here, CASC3 is linked to neuropathy.